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Venoms comprise mixtures of peptides and proteins tailored by Natural Selection to act on vital sys-
tems of the prey or victim. Here we review our proteomic protocols for uncoiling the composition,
immunological proﬁle, and evolution of snake venoms. Our long-term goal is to gain a deep insight
of all viperid venom proteomes. Knowledge of the inter- and intraspecies ontogenetic, individual,
and geographic venom variability has applied importance for the design of immunization protocols
aimed at producing more effective polyspeciﬁc antivenoms. A practical consequence of assessing the
cross-reactivity of heterologous antivenoms is the possibility of circumventing the restricted avail-
ability of species-speciﬁc antivenoms in some regions. Further, the high degree of target speciﬁcity
makes toxins valuable scaffolds for drug development.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. The Ying and Yang of animal venoms
Venomous organisms are widely spread throughout the animal
kingdom, comprising more than 100,000 species distributed
among all major phyla, such as chordates (reptiles, ﬁshes, amphib-
ians, mammals), echinoderms (starﬁshes, sea urchins), molluscs
(cone snails, octopi), annelids (leeches), nemertines, arthropods
(arachnids, insects, myriapods) and cnidarians (sea anemones, jel-
lyﬁsh, corals). In any habitat there is a competition for resources,
and every ecosystem on Earth supporting life contains poisonous
or venomous organisms. One of the most fascinating techniques
of capturing prey or defending oneself is the use of poisons or ven-
oms. Venom represents an adaptive trait and an example of con-
vergent evolution [1–3]. Venoms are deadly cocktails, each
comprising unique mixtures of peptides and proteins naturally tai-
lored by Natural Selection to act on vital systems of the prey or vic-
tim. Venom toxins disturb the activity of critical enzymes,
receptors, or ion channels, thus disarranging the central and
peripheral nervous systems, the cardiovascular and the neuromus-
cular systems, blood coagulation and homeostasis. On the other
hand, due to their high degree of target speciﬁcity, venom toxins
have been increasingly used as pharmacological tools and as proto-
types for drug development. The medicinal value of venoms has
been known from ancient times. The snake is a symbol of medicine
due to its association with Asclepius, the Greek god of medicine.chemical Societies. Published by EThe medical uses of scorpion and snake venoms are well docu-
mented in folk remedies, and in Western and Chinese traditional
medicine [4,5]. However, extensive investigations on venom com-
pounds as natural leads for the generation of pharmaceutical prod-
ucts have only been performed in the last decades, after a
bradykinin-potentiating peptide isolated from the venom of the
Brazilian viper Bothrops jararaca was developed in the 1950s into
the ﬁrst commercial angiotensin I-converting enzyme (ACE)-inhib-
iting drug, captopril, for the treatment of renovascular hyperten-
sion [6,7]. The latest example of development of a toxin into an
approved drug by the US Food and Drug Administration (FDA)
(December 2004) is ziconotide (Prialt), a synthetic non-opioid,
non-NSAID, non-local anesthetic drug originating from the cone
snail Conus magus peptidex-conotoxin M-VII-A, an N-type calcium
channel blocker. Discovered in the early 1980s [8], zicotonide is a
rare example of a molecule used unaltered from a creature’s chem-
istry. Prialt is used for the amelioration of chronic untreatable
pain, and due to the profound side effects or lack of efﬁcacy when
delivered through more common routes, such as orally or intrave-
nously, Prialt must be administered directly into the spine.
Venoms represent a huge and essentially unexplored reservoir
of bioactive components that may cure disease conditions which
do not respond to currently available therapies. The great pharma-
cological cornucopia accumulated by Nature over evolution has re-
sulted in true combinatorial libraries of hundreds of thousands of
potentially active and useful molecules synthesised in the venoms
of the 700 or so known species of Conus, the roughly 725 species oflsevier B.V. All rights reserved.
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known species of spiders, just to cite only a few examples of ven-
omous animals. The accelerated Darwinian evolution acting to pro-
mote high levels of variation in venom proteins may be part of a
predator–prey arms race that allows the predator to adapt to a
variety of different prey, each of which are most efﬁciently sub-
dued with a different venom formulation. In addition to under-
standing how venoms evolve, a major aim of venomic projects is
to gain a deeper insight into the spectrum of medically important
toxins in venoms to uncover clues in order to solve the riddle of the
medical effectiveness of venoms and to learn how to convert
deadly toxins into lifesaving drugs [9,10]. On the other hand,
envenomation constitutes a highly relevant public health issue
on a global basis, as there are venomous organisms in every conti-
nent and almost every country. However, venomous animals are
particularly abundant in tropical regions, which represent the
kitchen of evolution. Arthropod stings inﬂicted by bees, wasps,
ants, spiders, scorpions, and – to a lesser extent – millipedes and
centipedes, constitute the most common cause of envenoming by
animals, although around 80% of deaths by envenomation world-
wide are caused by snakebite, followed by scorpion stings, which
cause 15%. Envenoming constitutes a highly relevant public health
issue on a global basis, although it has been systematically ne-
glected by health authorities in many parts of the world [11–15].
Being a pathology mainly affecting young agricultural workers liv-
ing in villages far from health care centers in low-income countries
of Africa, Asia and Latin America, it must be regarded as a ‘ne-
glected tropical pathology’ [11]. Adequate treatment of envenom-
ing is critically dependent on the ability of antivenoms to
neutralize the lethal toxins reversing thereby the signs of enven-
oming. A long-term research goal of venomics of applied impor-
tance for improving current antivenom therapy is to understand
the molecular mechanisms and evolutionary forces that underlie
venom variation. Thus, a robust knowledge of venom composition
and of the onset of ontogenetic, individual, and geographic venom
variability may have an impact in the treatment of bite victims and
in the selection of specimens for the generation of improved anti-
dotes [16] (see below).2. The evolution of the advanced snakes and their venoms
The suborder of snakes (Serpentes) of the reptilian order Squa-
mata, named for their scaly skin, includes about 3000 extant spe-
cies placed in approximately 400 genera and 18 families (http://
www.reptile-database.org). The timing of major events in snake
evolution is not well understood, however, owing in part to a rel-
atively patchy and incomplete fossil record [17,18]. Nevertheless,
after more than 100 years of research, the most generalized phylo-
genetic view is that the group evolved from a family of terrestrial
lizards during the time of the dinosaurs in the Jurassic period,
about 200 million years (Myr) ago [19]. After the end of the non-
avian dinosaurs reign, around the Cretaceous-Tertiary boundary
65 Myr ago [20], the boids (the ancestors of boas, pythons and ana-
condas) were the dominant snake family on Earth. Within the
Cenozoic era that followed, advanced snakes (colubrids) arose as
long ago as in the Oligocene epoch (35–25 Myr). Colubrids, the
family which we regard today as typical snakes, remained a small
taxon until the tectonic plates drifted apart from the equator and
the cool climate pushed boids to disappear from many ecological
niches. Colubrids quickly colonized these empty habitats and this
family today comprises over two-thirds of all the living snake spe-
cies [21]. Colubroidea encompasses Viperidae (30 genera, 230 spe-
cies of vipers and pitvipers), Elapidae (63 genera, 272 species of
corals, mambas, cobras and their relatives), Atractaspididae (14
genera, 65 species of Stiletto snakes and mole vipers), and Colubri-dae (290 genera, almost 1700 species of rear-fanged and ‘‘harm-
less” colubrids) (http://www.reptile-database.org). Noteworthy,
the front-fanged venom-delivery system appeared three times
independently in Viperidae, Elapidae, and Atractaspididae [22].
The presence of a venom-secreting oral gland is a shared de-
rived character of the advanced (Caenophidia) snakes. All venom-
ous squamates, snakes and venomous lizards such as gila
monster, beaded lizard, komodo dragon, etc., share a common ven-
omous ancestor [1]. Given the central role that diet has played in
the adaptive radiation of snakes [23], venom thus represents a
key adaptation that has played an important role in the diversiﬁca-
tion of these animals. Venoms represent the critical innovation in
ophidian evolution that allowed advanced snakes to transition
from a mechanical (constriction) to a chemical (venom) means of
subduing and digesting prey larger than themselves, and as such,
venom proteins have multiple functions including immobilizing,
paralyzing, killing and digesting prey. Venoms of snakes in the
families Viperidae and Elapidae are produced in paired specialized
venom glands located in the upper jaw, ventral and posterior to the
eyes [24], and introduced deeply into prey tissues via elongate,
rotatable fangs. Viperids and elapids possess the most widely stud-
ied types of animal toxins [9,25,26]. These snake venoms contain
complex mixtures of hundreds of important pharmacologically ac-
tive molecules, including low molecular mass organic and inor-
ganic components (histamine and other allergens, polyamines,
alkaloids), small peptides and proteins [9,27,28]. The biological ef-
fects of venoms are complex because different components have
distinct actions and may, in addition, act in concert with other ve-
nom molecules. The synergistic action of venom proteins may en-
hance their activities or contribute to the spreading of toxins.
According to their major toxic effect in an envenomed animal,
snake venoms may be conveniently classiﬁed as neurotoxic and
haemotoxic. Among the ﬁrst group are the Elapidae snakes (mam-
bas, cobras, and particularly the Australian snakes, which are well
known to be the most toxic in the world). On the other hand,
snakes of the family Viperidae (vipers and pitvipers) contain
numerous proteins that typically disrupt the function of the coag-
ulation cascade, the haemostatic system and tissue integrity,
which are manifested as bleeding and incoagulable blood and local
tissue necrosis in human victims of envenoming [9,26,27].
The existence in the same venom of a diversity of proteins of the
same family but differing from each other in their pharmacological
effects reﬂects an accelerated positive Darwinian evolution. Venom
toxins likely evolved from proteins with a normal physiological
function and appear to have been recruited into the venom prote-
ome before the diversiﬁcation of the advanced snakes, at the base
of the Colubroid radiation [1,29,30]. Gene duplication followed by
functional divergence is the main source of molecular novelty.
Gene duplication creates redundancy and allows a gene copy to
be selectively expressed in the venom gland, escaping the pressure
of negative selection and evolving a new function through positive
selection and adaptative molecular evolution [31–33]. The occur-
rence of multiple isoforms within each major toxin family evi-
dences the emergence of paralogous groups of multigene families
across taxonomic lineages where gene duplication events occurred
prior to their divergence, and suggests an important role for bal-
ancing selection in maintaining high levels of functional variation
in venom proteins within populations. The mechanism leading to
this mode of selection is unclear but it has been speculated that
it may be related to unpredictability with which a sit-and-wait
predator like a rattlesnake encounters different types of prey, each
of which are most efﬁciently subdued with different venom pro-
teins [34,35]. Thus, to deal with this uncertainty, snakes are re-
quired to have a variety of proteins ‘‘available” in their venom at
all times to deal with different prey. The selection pressure leading
to high levels of variation in venom genes may parallel the selec-
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lution [36]. Understanding how toxin genes are regulated and how
toxins mutate in an accelerated fashion may reveal not only the
molecular basis for adaptive variations in snake phenotypes [35],
but also to learn how to use deadly toxins as therapeutic agents
[37].3. Snakebite envenoming and the challenge of generating
effective antivenoms
Snakebite envenoming constitutes a highly relevant public
health issue on a global basis, although it has been systematically
neglected by health authorities in many parts of the world [11–14].
The actual incidence of snakebite envenoming world wide and its
associated mortality are difﬁcult to estimate, since there are many
countries where this pathology is not appropriately reported, and
since epidemiological data are often fragmentary. Nevertheless, a
recently published study estimated at least 421,000 cases of
envenoming and 20,000 deaths yearly, though these largely hospi-
tal-based ﬁgures may be as high as 1,841,000 envenomings result-
ing in 94,000 deaths [14], and a previous report had estimated a
total of 2.5 million envenomings and over 125,000 deaths [38].
Even realizing that the actual impact of this pathology is likely to
be underestimated, because many of snakebite victims seek tradi-
tional treatment and may die at home unrecorded, it is evident that
snakebite envenoming occupies a prominent position as a public
health issue in many regions of the world. Moreover, an unknown
percentage of snakebite victims end up with permanent physical
disability, due to local necrosis, and with psychological sequelae,
both of which greatly jeopardize the quality of their lives. There-
fore, if this pathology is analyzed in terms of DALYs (‘disability-ad-
justed life years’) lost, its impact is even greater [39].
Adequate treatment of snakebite envenoming is critically
dependent on the ability of antivenoms to reverse venom-induced
coagulopathy, hemorrhage, hypotensive shock and other signs of
systemic envenoming. First generation antivenoms, described over
100 years ago [40,41], comprised unpuriﬁed serum from animals
hyperimmunised with venom. Current antivenoms consist of puri-
ﬁed immunoglobulins which have reduced the incidence and
severity of treatment-induced serum-sickness, anaphylactic shock,
and other adverse reactions. However, the venom-immunization
protocols have not changed in over a century and make no attempt
to direct the immune response to the most pathogenic venom pro-
teins (many venom proteins are not toxic and many low molecular
weight venom proteins are highly toxic but weakly immunogenic).
Consequently, the dose-efﬁcacy of antivenoms is thought to suffer
from the presence of redundant antibodies to non-toxic molecules
and a lack of potent neutralizing antibodies to small molecular
weight toxins. This in turn results in the need for high volumes
of antivenom to effect treatment and a consequent increase in
the risk of serum-sickness and anaphylactic adverse effects. On
the other hand, the immunization mixtures used for antivenom
production are speciﬁc for every country or region, due to the
intraspeciﬁc venom variability and to the fact that different snake
species are responsible for the majority of envenomings in differ-
ent countries. The inter- and intraspecies heterogeneity in venom
composition may account for differences in the clinical symptoms
observed in human victims of envenoming by the same snake spe-
cies in different geographical regions [42,43]. Understanding the
variation in antigenic constituents of venoms from snakes of dis-
tinct geographic origin represents thus a key challenge towards
the design of novel, toxin-speciﬁc approaches for the immunother-
apy of snake bite envenoming. Further, the high levels of intra- and
interspeciﬁc variation [42], which reﬂects local adaptations confer-
ring ﬁtness advantages to the snake population, and age-related(ontogenetic) changes in venom composition (possibly related to
diet differences between juvenile and adults of the same species)
[35], may also have an impact in the treatment of bite victims
and highlights the need of using pooled venoms as a substrate
for antivenom production. Developing toxin-speciﬁc antivenoms
is critically dependent upon a detailed knowledge of the venom
toxin composition and immunological proﬁles.
Qualitative individual differences in the composition of the ve-
nom of the same ophidian species are of fundamental importance
in snakebite pathology and therapeutics, since, as a rule, ophio-
toxicosis results from the venom of a single snake. Thus, knowl-
edge of inter- and intraspecies variability is necessary for the selec-
tion of the regions from which snake specimens have to be
collected for the preparation of venom pools. The reference venom
pool has to be obtained from a relatively large number of speci-
mens collected from different geographic regions within the distri-
bution range of the species. Intraspeciﬁc, geographic, and
ontogenetic variability in venom composition can be conveniently
analyzed using a combination of proteomic tools and toxicological
and biochemical functional assays. Below we describe the proto-
cols we have developed for analyzing in detail the composition
of venom proteomes (‘‘snake venomics”) and for investigating
which venom proteins bear epitopes recognized by an antivenom
and which ones escaped the immunological response of the hyper-
immunized animal (‘‘snake antivenomics”).4. Snake venomics: proteomic tools for studying the protein
composition of venoms
Venom proteomics has been under investigation since the very
earliest biochemical studies, though the ﬁeld has began to ﬂourish
owing to the recent application of mass spectrometry, coupled
with improvements of databases of venom protein sequences pro-
vided by transcriptomic analyses of venom glands, for the charac-
terization of toxin proteomes [44–46]. The signiﬁcance of
proteomic methodologies for biological research has been granted
by the pace of genome sequencing projects. However, organisms
with unsequenced genomes, including venomous animals and
snakes in particular, still represent the overwhelming majority of
species in the biosphere. We have designed a snake venomics ap-
proach (Fig. 1) which starts with the fractionation of the crude ve-
nom by reverse-phase HPLC (Fig. 1A), followed by the initial
characterization of each protein fraction by combination of N-ter-
minal sequencing, SDS–PAGE (or 2DE), and mass spectrometric
determination of the molecular masses and the cysteine (SH and
S–S) content [44].
Detection of proteins separated by reverse-phase HPLC is per-
formed at 215 nm. Given that the wavelength of absorbance for a
peptide bond is 190–230 nm, protein detection at 215 nm allows
an estimation of the relative abundances (expressed as percentage
of the total venom proteins) of the different protein families as
determined from the relationship between the sum of the areas
of the reverse-phase chromatographic peaks containing proteins
from the same family, and the total area of venom protein peaks
in the reverse-phase chromatogram. In a strict sense, and accord-
ing to the Lambert–Beer law, the calculated relative amounts cor-
respond to the ‘‘% of total peptide bonds in the sample”, which is a
good estimate of the % by weight (g/100 g) of a particular venom
component. Understanding how venoms work requires quantita-
tive data on the occurrence of individual toxins in a given venom.
Abundant venom proteins may perform generic killing and diges-
tive functions that are not prey speciﬁc whereas low abundance
proteins may be more plastic either in evolutionary or ecological
timescales. Mutations provide the ground on which natural selec-
tion operates to create functional innovations. A subset of low
Fig. 1. Snake venomics. Schematic representation of the steps typically followed in a snake venomics project. (A) Reverse-phase chromatographic separation of the venom
proteins; (B and C) SDS–PAGE of the RP-HPLC isolated proteins and determination of the molecular masses of the proteins isolated in panel A; (C) in-gel tryptic digestion of
protein bands; (D) amino acid sequence determination by nanospray-ionization CID–MS/MS of selected tryptic peptide ions; and (E) integration of results into toxin family
composition pies. For more details consult [44].
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to feeding on particular prey or may represent orphan molecules
evolving under neutral selection ‘‘in search for a function”. Hence,
whereas abundant proteins are the primary targets for immuno-
therapy, minor components may represent scaffolds for biotechno-
logical developments.
Protein fractions showing single electrophoretic band, molec-
ular mass, and N-terminal sequence (Fig. 1B) can be straightfor-
wardly assigned by BLAST analysis to a known protein family.
Thus, although few toxins from any given species are annotated
in the public-accessible databases, representative members of
most snake venom toxin families are present among the
1100 viperid toxin protein sequences belonging to 157 species
deposited to date in the SwissProt/TrEMBL database (Knowl-
edgebase Release 56.5 of November 2008; http://us.expasy.org/
sprot/). On the other hand, protein fractions showing heteroge-
neous or blocked N-termini are analyzed by SDS–PAGE and the
bands of interest subjected to automated reduction, carbami-
domethylation, and in-gel tryptic digestion (Fig. 1C). The result-
ing tryptic peptides are then analyzed by MALDI-TOF mass
ﬁngerprinting followed by amino acid sequence determination
of selected doubly- and triply-charged peptide ions by colli-
sion-induced dissociation tandem mass spectrometry. Except
for a few proteins, the peptide mass ﬁngerprinting approach
alone is unable to identify any protein in the databases. In addi-tion, as expected from the rapid amino acid sequence divergence
of venom proteins evolving under accelerated evolution [9,47],
with a few exceptions, the product ion spectra do not match
any known protein using the ProteinProspector (http://prospec-
tor.ucsf.edu) or the MASCOT (http://www.matrixscience.com)
search programs against the UniProtKB/Swiss-Prot entries from
taxon Serpentes (http://ca.expasy.org/cgi-bin/get-entries?view=
full&KW=Toxin&OC=Serpentes). Furthermore, it is not too unu-
sual that a product ion spectrum matched with high MASCOT
score to a particular peptide sequence corresponds actually to
a tryptic peptide of a homolog snake toxin containing one or
more nearly isobaric amino acid substitutions. Hence, it is neces-
sary to revise manually all the CID–MS/MS spectra (to conﬁrm
the assigned peptide sequence or for performing de novo
sequencing), and submit the deduced peptide ion sequences to
BLAST similarity searches. Although the lack of any complete
snake genome sequence is a serious drawback for the identiﬁca-
tion of venom proteins, high-quality MS/MS peptide ion frag-
mentation spectra usually yield sufﬁcient amino acid sequence
information derived from almost complete series of sequence-
speciﬁc b- and/or y-ions (Fig. 1D) to unambiguously identify a
homolog protein in the current databases. The combined venom-
ics strategy allows us to assign unambiguously all the isolated
venom toxins representing over 0.05% of the total venom pro-
teins to known protein families (Fig. 1E, Table 1).
Table 1
Overview of the relative occurrence of proteins (in percentage of the total HPLC-separated proteins) of the toxin families in the venoms of Sistrurus catenatus catenatus (SCC),
Sistrurus catenatus tergeminus (SCT), and Sistrurus catenatus edwardsii (SCE) from USA [34]; Sistrurus miliarius barbouri (SMB) from USA [52]; the Tunisian snakes Cerastes cerastes
cerastes (CCC), Cerastes vipera (CV) and Macrovipera lebetina transmediterranea (MLT) [48]; African Bitis arietans (BA) [50]; Bitis gabonica gabonica (BGG) [49]; Bitis gabonica
rhinoceros (BGR), Bitis nasicornis (BN), and Bitis caudalis (BC) [56]; Echis ocellatus (EO) [51]; Lachesis muta (LM) [53]; Crotalus atrox (CA), and Agkistrodon contortrix contortrix (ACC)
from USA (Calvete et al., unpublished); Armenian vipers Macrovipera lebetina obtusa (Mlo), and Vipera raddei (Vr) [54]; Atropoides picadoi (Api), and Atropoides mexicanus (Amex)
[57] from Costa Rica; Bothrops asper (Bas) from the Caribbean (C) and the Paciﬁc versants of Costa Rica [60]; Lesser Antillean pitvipers Bothrops caribbaeus (Bcar) (Santa Lucía), and
Bothrops lanceolatus (Blan) (Martinique) [58]; Brazilian Bothrops fonsecai (Bfon), and Bothrops cotiara (Bco) [59]; Bothriechis lateralis (Bolat), and Bothriechis schlegelii (Bosch) [55]
from Costa Rica; and Lachesis stenophrys (Lste) [53] from Costa Rica. Major toxin families in each venom are highlighted in boldface.
Venom
SCC SCT SCE SMB CCC CV MET BA BGG BGR BN BC EO LM CA ACC
Protein family % of total venom proteins
Disintegrins
– Long – – – – – – – 17.8 – – – – – – – –
– Medium 2.5 4.2 0.9 7.7 – – – – – – – – – – 6.5 –
– Dimeric – – – – 8.1 <1 6.0 – 3.4 8.5 3.5 – 4.2 – – 1.5
– Short – – – – – – <1 – – – – – 2.6 – – –
Myotoxin 0.4 <0.1 – – – – – – – – – – – – – –
C-type BPP/NP – – <0.1 <0.1 – – <1 – 2.8 0.3 – – – 14.7 2.1 <0.1
Kunitz-type inhibitor – – <0.1 <0.1 – – – 4.2 3.0 7.5 – 3.2 – – – –
Cystatin – – – – – – – 1.7 9.8 5.3 4.2 – – – – –
DC-fragment <0.1 <0.1 <0.1 1.3 – – 1.0 – 0.5 0.6 <0.1 – 1.7 – – <0.1
NGF/svVEGF <0.1 <0.1 <0.1 <0.1 – – 2.1 – 1.0 – – – – – – –
Ohanin-like – – – – – – – – – – – – – – – <0.1
CRISP 0.8 1.3 10.7 2.9 – – – – 2.0 1.2 1.3 1.2 1.5 1.8 4.2 –
PLA2 29.9 31.6 13.7 32.5 20.0 21.1 4.0 4.3 11.4 4.8 20.1 59.8 12.6 8.7 16.3 18.5
Serine proteinase 18.2 20.4 24.4 17.1 9.1 20.0 9.2 19.5 26.4 23.9 21.9 15.1 2.0 31.2 10.1 13.8
C-type lectin-like <0.1 <0.1 <0.1 <0.1 24.0 0.9 10.1 13.2 14.3 14.1 4.2 4.9 7.0 8.1 1.6 –
L-amino acid oxidase 4.2 1.6 2.5 2.1 12.0 9.0 – – 1.3 2.2 3.2 1.7 1.4 2.7 8.0 2.2
Zn2+-metalloproteinase 43.8 40.6 48.6 36.1 37.0 48.1 67.1 38.5 22.9 30.8 40.9 11.5 67.0 31.9 51.1 63.6
Mlo Vr Api Amex Bas(C) Bas(P) Bear Blan Bco Bfon Bolat Bosch Lste
– Long – – – – – – 1.5 – – – – – –
– Medium – – <0.1 2.5 2.1 1.4 – – 1.2 4.4 – – –
– Dimeric 8.5 9.7 – – – – – – – – – – –
– Short 2.8 – – – – – – – – – – – –
Myotoxin – – – – – – – – – – – – –
C-type BPP/NP 5.3 6.0 1.8 8.6 – – – – – – 11.1 13.4 14.7
Kunitz-type inhibitor – 0.1 – – – – – – – – – – –
Kazal-type inhibitor – – – – – – – – – – – 8.3 –
Cystatin – – – – – – – – – – – – –
DC-fragment 1.7 0.1 <0.1 <0.1 <0.1 <0.1 <0.2 – 0.5 0.7 – – –
NGF/svVEGF – 2.4 <0.1 <0.1 – – – – 3.3 3.9 0.5 – 0.4
Ohanin-like – – – – – – – – – – – – –
3-Finger toxin – – – <0.1 – – – – – – – – –
CRISP 2.6 7.4 4.8 1.9 0.1 0.1 2.6 – 3.6 2.4 6.5 2.1 –
PLA2 14.6 23.8 9.5 36.5 28.8 45.1 12.8 8.6 – 30.1 8.7 43.8 12.3
Serine proteinase 14.9 8.4 13.5 22.0 18.2 4.4 4.7 14.4 14.4 4.1 11.3 5.8 25.6
C-type lectin-like 14.8 9.6 1.8 1.3 0.5 0.5 – <0.1 <0.1 9.8 0.9 – 3.6
L-amino acid oxidase 1.7 0.2 2.2 9.1 9.2 4.6 8.4 2.8 3.8 1.9 6.1 8.9 5.3
Zn2+-metalloproteinase 32.1 31.6 66.4 18.2 41.0 44.0 68.6 74.3 73.1 42.5 55.1 17.7 38.2
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analysis of all viperid venomes. To date, this methodology has been
applied to explore the venom proteomes (Table 1) of the medi-
cally-relevant Tunisian vipers Cerastes cerastes, Cerastes vipera,
Macrovipera lebetina [48]; African Bitis gabonica [49], Bitis arietans
[50], and Echis ocellatus [51]; North American Sistrurus miliarius
barbouri [52] and Sistrurus catenatus subspecies [34]; the South
and Central American Lachesis sp. [53]; the Armenian mountain vi-
pers Vipera raddei and Macrovipera lebetina obtusa [54]; the arbo-
real Neotropical pitvipers Bothriechis lateralis and Bothriechis
schlegelii [55]; to infer phylogenetic alliances within genus Bitis
[56] and Sistrurus [34]; to rationalize the envenomation proﬁles
of Atropoides [57] and Bothrops [58] species; to deﬁne venom-
associated taxonomic markers [59]; to establish the molecular ba-
sis of geographic, individual, and ontogenetic venom variations in
Bothrops asper [60]; and to contribute to reconstruct the natural
history and cladogenesis of Bothrops colombiensis [61], a medically
important pitviper of the Bothrops atrox-asper complex endemic to
Venezuela. A few other laboratories have reported qualitative pro-
teomic studies on several venoms, including those from the Euro-pean vipers, Vipera ammodytes ammodytes and Vipera ammodytes
meridionalis [62], Asian Daboia russelli siamensis [63], Amazonian
Bothrops atrox [64], and Brazilian Bothrops insularis [65].
Qualitative discrepancies in the compositional agreement of ve-
nom acquired using proteomic and transcriptomic approaches
have been reported, i.e. for Lachesis muta [53], Bitis gabonica gabo-
nica [49], and Echis ocellatus [51]. Venom composition may be
inﬂuenced by a number of different factors, most notably the po-
tential for genetic drift on account of (i) gender based variation
and (ii) ontogenetic variations. Conversely, the occurrence of
mRNAs that are abundant and readily identiﬁable in the transcrip-
tome, yet apparently absent from the venom proteome may also be
explained by a number of factors. Firstly, these messengers may
exhibit transient, individual or a temporal expression patterns over
the life time of the snake. Alternatively, mRNAs whose predicted
polypeptides were not found to be secreted in venom may repre-
sent very low abundance toxins that play a hitherto unrecognised
physiological function in the venom gland, or may simply repre-
sent a hidden repertoire of non-translated orphan molecules which
may eventually become functional for the adaptation of snakes to
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the ﬁnal composition of venom is inﬂuenced by transcriptional and
post-translational mechanisms that may be more complex than
previously appreciated. Nevertheless, a major conclusion drawn
from snake venomics and transcriptomic analyses of viperid ve-
nom glands is that despite venoms being complex mixture of pro-
teins, venom proteins belong to only a few major families,
including enzymes (serine proteinases, Zn2+-metalloproteases,
L-amino acid oxidase, PLA2) and proteins without enzymatic activ-
ity (disintegrins, C-type lectins, natriuretic peptides, ohanin, myo-
toxins, CRISP toxins, nerve and vascular endothelium growth
factors, cystatin and Kunitz-type protease inhibitors) [16,44]
(Table 1), though different venoms exhibit a distinct toxin family
distributional proﬁle (Table 1). This situation may reﬂect the fact
that toxins likely evolved from a restricted set of protein families,
and opens the door for a rationale design of intra-, but also inter-,
species family-speciﬁc neutralizing antibodies.
Several antivenoms are produced in Latin America using differ-
ent venoms in the immunization schemes [66]. Each of these anti-
venoms is effective in variable degree against envenomations by
snake venoms not included in the immunization protocol, demon-
strating the high degree of immunological cross-reactivity be-
tween Central and South American crotaline snake venoms. A
practical consequence of this fortunate circumstance is the possi-
bility of using these heterologous antivenoms to circumvent the
restricted availability of species-speciﬁc antivenoms in some re-
gions. However, before testing in clinical trials, antivenoms need
to be evaluated experimentally by assessing their neutralizing abil-
ity against the most relevant toxic and enzymatic activities of
snake venoms. To this end, we have developed a simple proteomic
protocol for investigating the immunoreactivity, and thus the po-
tential therapeutic usefulness, of antivenoms towards homologous
and heterologous venoms.
5. Antivenomics: proteomic tools for studying the
immunological proﬁle of venoms
We have coined the term ‘‘antivenomics” for the identiﬁcation
of venom proteins bearing epitopes recognized by an antivenom
using proteomic techniques [55,58,61]. Antivenomics is based on
the immunodepletion of toxins upon incubation of whole venomFig. 2. Antivenomics. Panel A displays the reverse-phase HPLC separation of the venom
not immunodepleted by the Costa Rican polyvalent (Crotalinae) ICP antivenom. These N
molecule (15). The orange arrow points to the major snake venom metalloproteinase (S
results fully explain the incapacity of the ICP antivenom to neutralize the neurotoxicity o
large content of the heterodimeric PLA2 Crotoxin (Panel B). Similarly, antivenoms produ
American Crotalus simus but are ineffective at neutralizing the hemorrhagic activity of v
almost absence of hemorrhagic SVMPs (fractions 17–18 in reverse-phase chromatogram
antivenomic ﬁndings suggest that an antivenom raised against a mixture of C. simus an
effects of Middle and South American Crotalus species.with antivenom followed by the addition of a secondary antibody.
Antigen-antibody complexes immunodepleted from the reaction
mixture contain the toxins against which antibodies in the anti-
venom are directed. By contrast, venom components that remain
in the supernatant are those which failed to raise antibodies in
the antivenom, or which triggered the production of low-afﬁnity
antibodies. These components can be easily identiﬁed by compar-
ison of reverse-phase HPLC separation of the non-precipitated frac-
tion with the HPLC pattern of the whole venom previously
characterized by venomics. According to their immunoreactivity
towards antivenoms, toxins may be conveniently classiﬁed as: C-
toxins, completely immunodepletable toxins; P-toxins, partly
immunodepleted toxins; and N-toxins, non-inmunodepleted pro-
teins (Fig. 2). Assuming a link between the in vitro toxin immun-
odepletion capability of an antivenom and its in vivo neutralizing
activity towards the same toxin molecules, improved immuniza-
tion protocols should make use of mixtures of immunogens to gen-
erate high-afﬁnity antibodies against class P and class N toxins. On
the other hand, our antivenomics approach is simple and easy to
implement in any protein chemistry laboratory, and may thus rep-
resent another useful protocol for investigating the immunoreac-
tivity, and thus the potential therapeutic usefulness, of
antivenoms towards homologous and heterologous venoms [16].
The deﬁcit (‘crisis’) of antivenom supply in some regions of the
world can be addressed to a certain extent by optimizing the use of
existing antivenoms and through the design of novel immuniza-
tion mixtures for producing broad-range polyspeciﬁc antivenoms.
Proteomics-based immunochemical analysis (antivenomics) pro-
vides relevant information for outlining which venom mixtures
cross-react with the most important components in medically-
relevant venoms from a particular region. This type of approach
may set the basis for the development of antivenoms on an
immunologically sound basis. The potential value of antivenomics,
together with preclinical neutralization tests, in assessing antiven-
om cross-reactivity is clearly illustrated by the following examples.
A highly effective antivenom (Sanoﬁ-Pasteur ‘Bothrofav’) has
been developed for the treatment of envenomings by Bothrops
lanceolatus, endemic to the Lesser Antillean island of Martinique.
It exhibits an excellent preclinical proﬁle of neutralization [67]
and its timely administration prevents the development of the
most serious effects of envenoming, including thrombosisproteins from Crotalus simus (from Costa Rica). Red arrows indicate venom proteins
-toxins were identiﬁed as disintegrins (4–8), crotoxin subunits (9–12), and a PLA2
VMP), which was partly immunodepleted by the ICP antivenom. The antivenomics
f the venom of South American Crotalus durissus subspecies, which is associated to a
ced in South America against C.d. terriﬁcus venom neutralize the lethality of Central
enom from genus Crotalus. Such neutralizing proﬁle is also fully explained by the
shown in B) in the C.d. terriﬁcus venom used in the immunization protocol. The
d C.d. terriﬁcus may effectively neutralize both the hemorrhagic and the neurotoxic
1742 J.J. Calvete et al. / FEBS Letters 583 (2009) 1736–1743[68,69]. However, the restricted availability of the antivenom in
the neighboring island of Saint Lucia and in zoos and herpetariums
is a matter of concern. Gutiérrez and colleagues have performed
detailed proteomic studies of the venoms of Bothrops caribbaeus
and B. lanceolatus and have evaluated the immunoreactivity of a
Crotalinae polyvalent antivenom produced in Costa Rica (by immu-
nization of horses with a mixture of equal amounts of the venoms
ofB. asper, Crotalus simus, and Lachesis stenophrys) towards the ven-
oms of B. caribbaeus and B. lanceolatus [58]. This study showed that
the antivenom immunodepleted 80% of the proteins from both B.
caribbaeus and B. lanceolatus venoms, and was effective in neutral-
izing the lethal, hemorrhagic, PLA2 and proteolytic activities of the
two venoms.
Calvete and co-workers from Venezuela and Costa Rica have
compared the venom proteomes of B. colombiensis, B. asper, and
B. atrox using venomics and antivenomics approaches [61]. This
study did not support the suggested synonymy between B. colom-
biensis and B. atrox. On the other hand, the closest homologs to B.
colombiensis venom proteins appeared to be toxins from B. asper.
A rough estimation of the similarity between the venoms of B.
colombiensis and B. asper indicated that these species share approx-
imately 65–70% of their venom proteomes. The close kinship of B.
colombiensis and B. asper points at the ancestor of B. colombiensis as
the founding Central American B. asper ancestor. This ﬁnding may
be relevant for reconstructing the natural history and cladogenesis
of Bothrops. Further, the virtually indistinguishable immunological
cross-reactivity of a Venezuelan ABC antiserum (raised against a
mixture of B. colombiensis and Crotalus durissus cumanensis ven-
oms) and the Costa Rican ICP polyvalent antivenom (generated
against a mixture of B. asper, C. simus, and L. stenophrys venoms) to-
wards the venoms of B. colombiensis and B. asper, supports this
view and suggests the possibility of indistinctly using these anti-
venoms for the management of snakebites by any of these Bothr-
ops species.
An antivenom manufactured in Costa Rica using venom of the
Central American rattlesnake (Crotalus simus simus) population, is
ineffective for neutralizing the neurotoxic activity of South Amer-
ican Crotalus durissus terriﬁcus. Similarly, antivenoms produced in
South America against C.d. terriﬁcus venom neutralize the neuro-
toxicity of Central American venoms but are ineffective at neutral-
izing the hemorrhagic activity of venoms from genus Crotalus [70].
Such neutralizing proﬁle is fully explained by the proteomic and
antivenomic characterization of Crotalus (simus and durissus) ven-
oms described in Fig. 2. The case of Crotalus illustrates how the
knowledge of venom variations and their geographical distribution
can lead to securing venoms with a more deﬁned composition for
preparing venom mixtures for the generation of antivenoms effec-
tive against the venoms of rattlesnakes from Central and South
America.
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